FDA Determines Regulatory Review Period for EXXUA Patent Extension Application

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for EXXUA, a human drug product, following the submission of a patent extension application to the U.S. Patent and Trademark Office (USPTO).